Cytotoxic drugs in drinking water: A prediction and risk assessment exercise for the Thames catchment in the United Kingdom

Environmental Toxicology and Chemistry

Volumn 28, Issue 12, 2009, Pages 2733-2743

  Rowney, Nicole C ^a   Johnson, Andrew C ^b   Williams, Richard J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

Author keywords

Cytotoxic drugs; Drinking water; Low flows 2000 ; Risk assessment; Wastewater

Indexed keywords

ALKYLATING AGENTS; CYTOTOXIC; CYTOTOXIC DRUGS; DRINKING WATER; LOW FLOW; LOW FLOW CONDITION; PREGNANT WOMAN; RIVER THAMES; SYSTEM-BASED; TAP WATER; UNITED KINGDOM; UPPER BOUNDARY; WATER QUALITY MODELS;

ANTIBIOTICS; CATCHMENTS; CHEMICAL OXYGEN DEMAND; MUTAGENS; RISK ASSESSMENT; RISK MANAGEMENT; RUNOFF; SEWAGE; SEWAGE TREATMENT; WASTEWATER; WATER POLLUTION; WATER QUALITY;

POTABLE WATER;

ANTHRACYCLINE ANTIBIOTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; DRINKING WATER; EPIRUBICIN; FLUDARABINE; GEMCITABINE; OXALIPLATIN; TEMOZOLOMIDE;

CATCHMENT; CONCENTRATION (COMPOSITION); DRINKING WATER; DRUG; ECOTOXICOLOGY; HEALTH RISK; RISK ASSESSMENT; SEWAGE TREATMENT; WASTEWATER; WATER QUALITY;

ARTICLE; DRUG EXCRETION; DRUG USE; FLUID INTAKE; PRIORITY JOURNAL; SEWAGE EFFLUENT; SEWAGE TREATMENT; UNITED KINGDOM; WATER CONTENT; WATER MANAGEMENT; WATER QUALITY;

ANTINEOPLASTIC AGENTS; GREAT BRITAIN; HUMANS; RISK ASSESSMENT; WATER POLLUTANTS, CHEMICAL; WATER SUPPLY;

ENGLAND; THAMES BASIN; UNITED KINGDOM;

EID: 73449147015     PISSN: 07307268     EISSN: None     Source Type: Journal    
DOI: 10.1897/09-067.1     Document Type: Article

References (79)

1. Jones O, Voulvoulis N, Lester JN. 2005. Human pharmaceuticals in wastewater treatment processes. Crit Rev Environ Sci Technol 35:401-427.
2. Thrall L. 2006. Can drugs found in water harm humans? Environ Sci Technol 40:2072-2073.
3. Heberer T. 2002. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: A review of recent research data. Toxicol Lett 131:5-17.
4. Richardson ML, Bowron JM. 1985. The fate of pharmaceutical chemicals in the aquatic environment. J Pharm Pharmacol 37:1-12.
5. Zwiener C. 2007. Occurrence and analysis of pharmaceuticals and their transformation products in drinking water treatment. Anal Bioanal Chem 387:1159-1162.
6. Jobling S, Williams RJ, Johnson AC, Taylor A, Gross-Sorokin M, Nolan M, Tyler CR, Van Aerle R, Santos E, Brighty G. 2006. Predicted exposures to steroid estrogens in UK rivers correlate with widespread sexual disruption in wild fish populations. Environ Health Perspect 114(Suppl. 1):32-39.
7. Green RE, Taggart MA, Senacha KR, Raghavan B, Pain DJ, Jhala Y, Cuthbert R. 2007. Rate of decline of the oriental white-backed vulture population in India estimated from a survey of diclofenac residues in carcasses of ungulates. PLoS One 2: e686.
8. Chen M, Ohman K, Metcalfe C, Ikonomou M, Amatya P, Wilson J. 2006. Pharmaceuticals and endocrine disruptors in wastewater treatment effluents and in the water supply system of Calgary, Alberta, Canada. Water Qual Res J Can 40:351-364.
9. Snyder SA. 2008. Occurrence, treatment, and toxicological relevance of EDCs and pharmaceuticals in water. Ozone Sci Eng 30:65-69.
10. Heberer T. 2002. Tracking persistent pharmaceutical residues from municipal sewage to drinking water. J Hydrol 266:175-189.
11. Johnson AC, Jurgens MD, Williams RJ, Kummerer K, Kortenkamp A, Sumpter JP. 2008. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J Hydrol 348:167-175.
12. Webb S, Ternes T, Gibert M, Olejniczak K. 2003. Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett 142:157-167.
13. Collier AC. 2007. Pharmaceutical contaminants in potable water: Potential concerns for pregnant women and children. EcoHealth 4:164-171.
14. Kummerer K. 2001. Drugs in the environment: Emission of drugs, diagnostic aids and disinfectants into wastewater by hospitals in relation to other sources - A review. Chemosphere 45:957-969.
15. Marsh TJ, Hannafoird J, eds. 2008. UK Hydrometrie Register. Hydrological Data UK Series. Centre for Ecology and Hydrology. Alden Group, Oxfordshire, UK, p 210.
16. Hannaford J, Marsh TJ. 2006. An assessment of trends in UK runoff and low flows using a network of undisturbed catchments. International Journal of Climatology 26:1237-1253.
17. Renwick AG, Hillier K, Waller DG. 2005. Medical Pharmacology and Therapeutics, 2nd ed. Elsevier Saunders, Edinburgh, UK.
18. Skeel RT. 1999. Handbook of Cancer Chemotherapy, 5th ed. Lippincott Williams & Wilkins, London, UK.
19. Macpherson IRJ, Cassidy J. 2008. Challenges in combinational oncology studies. Pharm Med 22:85-97.
20. Kortenkamp A, Faust M, Scholze M, Backhaus T. 2007. Low-level exposure to multiple chemicals: Reason for human health concerns? Environ Health Perspect 115(Suppl. 1):106-114.
21. Cleuvers M. 2003. Aquatic ecotoxicity of pharmaceuticals including the assessment of combination effects. Toxicol Lett 142:185-194.
22. Pomati F, Castiglioni S, Zuccato E, Fanelli R, Vigetti D, Rossetti C, Calamari D. 2006. Effects of a complex mixture of therapeutic drugs at environmental levels on human embryonic cells. Environ Sci Technol 40:2442-2447.
23. Thames Cancer Registry. 2007. Cancer in South East England 2005. Thames Cancer Registry, London, UK.
24. Department of Health. 2004. Variations in usage of cancer drugs approved by NICE. Report of the Review undertaken by the National Cancer Director, Gateway number: 3366. London, UK.
25. Department of Health. 2006. Usage of cancer drugs approved by NICE. National Cancer Director's Report, Gateway number: 7124. London, UK.
26. Aungst BJ. 1993. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 82:979-987.
27. Ahn BZ, Sok DE. 1996. Michael acceptors as a tool for anticancer drug design. Curr Pharm Des 2:247-267.
28. Zounkova R, Odraska P, Dolezalova L, Hilscherova K, Marsalek B, Blaha L. 2007. Ecotoxicity and genotoxicity assessment of cytostatic pharmaceuticals. Environ Toxicol Chem 26:2208-2214.
29. Dollery CT. 1991. Therapeutic Drugs. Churchill Livingstone, Philadelphia, PA, USA.
30. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. 1984. Pharmacokinetics of cis-Diammine-1,1-Cyclobutane Dicarboxylate Platinum(H) in Patients with Normal and Impaired Renal Function. Waverly Press, Baltimore, MD, USA.
31. Leévi F, Metzger G, Massari C, Milano G. 2000. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38:1-21.
32. Moffat AC, Osselton D, Widdop B. 2002. Clarke's Isolation and Identification of Drugs: In Pharmaceuticals, Body Fluids, and Postmortem Material. Pharmaceutical Press, London, UK.
33. Ren S, Kalhorn TF, McDonald GB, Anasetti C, Appelbaum FR, Slattery JT. 1998. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 64:289-301.
34. Shen F, Decosterd LA, Gander M, Leyvraz S, Biollaz J, Lejeune F. 1995. Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B 667:291-300.
35. Lenz K, Hann S, Koellensperger G, Stefanka Z, Stingeder G, Weissenbacher N, Mahnik SN, Fuerhacker M. 2005. Presence of cancerostatic platinum compounds in hospital wastewater and possible elimination by adsorption to activated sludge. Sci Total Environ 345:141-152.
36. Lenz K, Mahnik SN, Weissenbacher N, Mader RM, Krenn P, Hann S, Koellensperger G, Uhl M, Knasmuller S, Ferk F, Bursch W, Fuerhacker M. 2007. Monitoring, removal and risk assessment of cytostatic drugs in hospital wastewater. Water Sci Technol 56:141-149.
37. Saravanan G, Ravikumar M, Jadhav MJ, Suryanarayana MV, Someswararao N, Acharyulu PVR. 2007. A stability-indicating LC assay and degradation behavior of temozolomide drug substances. Chromatographia 66:291-294.
38. Steger-Hartmann T, Kummerer K, Schecker J. 1996. Trace analysis of the antineoplastics ifosfamide and cyclophosphamide in sewage water by two-step solid-phase extraction and gas chromatography-mass spectrometry. J Chromatogr A 726:179-184.
39. Steger-Hartmann T, Kummerer K, Hartmann A. 1997. Biological degradation of cyclophosphamide and its occurrence in sewage water. Ecotoxicol Environ Saf 36:174-179.
40. Buerge IJ, Buser H, Poiger T, Muller MD. 2006. Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. Environ Sci Technol 40:7242-7250.
41. Kiffmeyer T, Gotze H, Jursch M, Luders U. 1998. Trace enrichment, chromatographic separation and biodegradation of cytostatic compounds in surface water. Fresenius' J Anal Chem 361:185-191.
42. Moldovan Z. 2006. Occurrences of pharmaceutical and personal care products as micropollutants in rivers from Romania. Chemosphere 64:1808-1817.
43. Reigner B, Blesch K, Weidekamm E. 2001. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85-104.
44. Mahnik SN, Lenz K, Weissenbacher N, Mader RM, Fuerhacker M. 2007. Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. Chemosphere 66:30-37.
45. Kummerer K, Al-Ahmad A. 1997. Biodegradability of the anti-tumour agents 5-fluorouracil, cytarabine, and gemcitabine: Impact of the chemical structure and synergistic toxicity with hospital effluent. Acta Hydrochim Hydrobiol 25:166-172.
46. Hall GD, Patel PM, Protheroe AS. 1998. Key Topics in Oncology. BIOS Scientific, Oxford, UK.
47. Mahnik SN, Rizovski B, Fuerhacker M, Mader RM. 2006. Development of an analytical method for the determination of anthracyclines in hospital effluents. Chemosphere 65: 1419-1425.
48. Christensen FM. 1998. Pharmaceuticals in the Environment - A Human Risk? Regul Toxicol Pharmacol 28:212-221.
49. Young AR, Grew R, Holmes MGR. 2003. Low Flows 2000: A national water resources assessment and decision support tool. Water Sci Technol 48:119-126.
50. Feijtel T, Boeije G, Matthies M, Young A, Morris G, Gandolfi C, Hansen B, Fox K, Holt M, Koch V, Schroder R, Cassani G, Schowanek D, Rosenblom J, Niessen H. 1997. Development of a geography-referenced regional exposure assessment tool for European rivers - GREAT-ER contribution to GREAT-ER #1. Chemosphere 34:2351-2373.
51. Koormann F, Rominger J, Schowanek D, Wagner JO, Schroder R, Wind T, Silvani M, Whelan MJ. 2006. Modeling the fate of down-the-drain chemicals in rivers: An improved software for GREAT-ER. Environmental Modelling & Software 21:925-936.
52. Williams RJ, Keller VDJ, Johnson AC, Young AR, Holmes MGR, Wells C, Gross-Sorokin M, Benstead R. 2009. A national risk assessment for intersex in fish arising from steroid estrogens. Environ Toxicol Chem 28:220-230.
53. Evans H, Bauer M, Goodman N, Hague J, Ta T. 2003. The role of ozone in improving drinking water quaüty in London and Oxford. Ozone Sci Eng 25:409-416.
54. Huber MM, Gobel A, Joss A, Hermann N, Loffler D, McArdell CS, Ried A, Siegrist H, Ternes TA, Von Gunten U. 2005. Oxidation of pharmaceuticals during ozonation of municipal wastewater effluents: A pilot study. Environ Sci Technol 39:4290-4299.
55. Stackelberg PE, Furlong ET, Meyer MT, Zaugg SD, Henderson AK, Reissman DB. 2004. Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water-treatment plant. Sci Total Environ 329:99-113.
56. Ternes TA, Meisenheimer M, McDowell D, Sacher F, Brauch H, Haist-Gulde B, Preuss G, Wilme U, Zulei-Seibert N. 2002. Removal of pharmaceuticals during drinking water treatment. Environ Sci Technol 36:3855-3863.
57. Wigton A, Kilduff JE. 2004. Modeling trichloroethylene adsorption by activated carbon preloaded with natural dissolved organic matter using a modified IAST approach. Environ Sci Technol 38: 5825-5833.
58. Carter MC, Weber WJ Jr, Olmstead KP. 1992. Effects of background dissolved organic matter on TCE adsorption by GAC. J Am Water Works Assoc 84:81-91.
59. Loper JC, Tabor MW, Rosenblum L. 1986. Mutagenic residues recovered from granular activated carbon after use in drinking water treatment. Water Chlorination 5:1329-1339.
60. Foster DM, Rachwal AJ, White SL. 1991. New treatment processes for pesticides and chlorinated organics control in drinking water. Journal of the Institution of Water and Environmental Management 5:466-477.
61. Foster DM, Rachwal AJ, White SL. 1992. Advanced treatment for the removal of atrazine and other pesticides. Water Supply 10:133-146.
62. 2. Water Sci Technol 57:195-200.
63. Rey RP, Padron AS, Leon LG, Pozo MM, Baluja C. 1999. Ozonation of cytostatics in water medium. Nitrogen bases. Ozone Sci Eng 21:69-77.
64. European Community/Scientific Committee on Consumer Products, Scientific Committee on Health and Environmental Risks, and Scientific Committee on Emerging and Newly-Identified Health Risks. 2008. Draft Opinion on Use of the Threshold of Toxicological Concern (TTC) Approach for the Safety Assessment of Chemical Substances. European Commission, Brussels, Belgium.
65. Keil F, Bechmann G, Kummerer K, Schramm E. 2008. Systemic risk governance for pharmaceuticals residues in drinking water. GAIA - Ecological Perspectives for Science and Society 17:355-361.
66. European Medicines Agency. 2006. European Medicines Evaluation Agency, Committee for Medicinal Products for Human Use (CHMP), Guideline on the Limits of Genotoxic Impurities, CPMP/SWP/5199/02. London, UK.
67. Kroes R, Renwick AG, Cheeseman M, Kleiner J, Mangelsdorf I, Piersma A, Schilter B, Schlatter J, Van Schothorst F, Vos JG, Wurtzen G. 2004. Structure-based thresholds of toxicological concern (TTC): Guidance for application to substances present at low levels in the diet. Food Chem Toxicol 42:65-83.
68. Schulman LJ, Sargent EV, Naumann BD, Faria EC, Dolan DG, Wargo JP. 2002. A human health risk assessment of pharmaceuticals in the aquatic environment. Human Ecol Risk Assess 8:657-680.
69. Ladou J. 2003. Current Occupational and Environmental Medicine, 3rd ed. Appleton & Lange, McGraw-Hill, New York, NY, USA.
70. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, Sklar CA. 2007. Decreased adult height in survivors of childhood acute lymphoblastic leukemia: A report from the childhood cancer survivor study. J Pediatr 150:370-375.
71. Mone SM, Gillman MW, Miller TL, Herman EH, Lipshultz SE. 2004. Effects of environmental exposures on the cardiovascular system: Prenatal period through adolescence. Pediatrics 113:1058-1069.
72. Diaz-Nieto J, WUby RL. 2005. A comparison of statistical downscaling and climate change factor methods: Impacts on low flows in the River Thames, United Kingdom, Clim Change 69:245-268.
73. Brunton LL, Lazo JS, Parker KL, Gilman AG, Goodman LS. 2006. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th ed. McGraw-Hill, New York, NY, USA.
74. Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB. 1995. Cyclophosphamide: Review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 330:115-181.
75. Bagley CM Jr, Bostick FW, Devita VT Jr. 1973. Clinical pharmacology of cyclophosphamide. Cancer Res 33:226-233.
76. Kummerer K, AI-Ahmad A, Bertram B, Wieβler M. 2000. Biodegradability of antineoplastic compounds in screening tests: Influence of glucosidation and of stereochemistry. Chemosphere 40:767-773.
77. Al-Ahmad A, Daschner FD, Kummerer K. 1999. Biodegradability of cefotiam, ciprofloxacin, meropenem, penicilhn G, and sulfamethoxazole and inhibition of waste water bacteria. Arch Environ Contam Toxicol 37:158-163.
78. Gandhi V, Plunkett W. 2002. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41:93-103.
79. Camaggi CM, Comparsi R, Strocche E, Testoni F, Angelelli B, Pannuti F. 1998. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 21:221-228.